Therefore, our findings suggest that the inherent immunogenic nature of sarcomatoid carcinoma might allow for favorable responses to chemo-immunotherapy even in the absence of high PD-L1 expression, highlighting that patients in this subgroup should not be excluded from this therapeutic option. Here, CD274 is linked to sarcomatoid carcinoma.